Autologous Killer Cell Therapy in Colon Cancer Patients

Colon Cancer Stage IV Clinical Trial

Official title:
Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients

Status Recruiting

Clinical Trial Summary

This study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis. 20 patients with confirmed stage IV colon carcinoma with metastasis will be assigned into two groups. Patients in both groups will receive the same therapeutic regimen as usual. Patients in one group additionally will be treated with a single infusion of autologous killer cells that had been previously prepared from peripheral blood.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03329664
Study type	Interventional
Source	Sabz Biomedicals
Contact	Naser Ahmadbeigi, Ph.D
Phone	+9821-82415103
Email	n-ahmadbeigi@sina.tums.ac.ir
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	February 9, 2020
Completion date	January 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Withdrawn	`NCT05310565` - The Effects of Chiropractic in Adults With Colon Cancer	N/A
Not yet recruiting	`NCT04035096` - The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients	Phase 1/Phase 2